Monitoring of magnetic targeting to tumor vasculature through MRI and biodistribution

Nanomedicine

Volumn 5, Issue 8, 2010, Pages 1173-1182

  Gultepe, Evin ^a   Reynoso, Francisco J ^a   Jhaveri, Aditi ^a   Kulkarni, Praveen ^a   Nagesha, Dattatri ^a   Ferris, Craig ^a   Harisinghani, Mukesh ^b   Campbell, Robert B ^a   Sridhar, Srinivas ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

biodistribution; magnetic targeting; magnetoliposomes; melanoma skin cancer; MRI; novel drug delivery systems; toxicology

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; CATION; INDIUM 111; LIPOSOME; SUPERPARAMAGNETIC IRON OXIDE; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER THERAPY; CONTRAST ENHANCEMENT; DRUG DELIVERY SYSTEM; MALE; MELANOMA B16; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RADIOACTIVITY; RELAXATION TIME; SCID MOUSE; TISSUE DISTRIBUTION; TUMOR GROWTH; TUMOR VASCULARIZATION;

ANIMALS; CONTRAST MEDIA; DRUG CARRIERS; FATTY ACIDS, MONOUNSATURATED; FERRIC COMPOUNDS; FLUORESCENT DYES; HUMANS; INJECTIONS, INTRAVENOUS; KINETICS; LIPOSOMES; MAGNETIC RESONANCE IMAGING; MAGNETICS; MELANOMA; MICE; MICE, SCID; NANOPARTICLES; NEOPLASM METASTASIS; NEOPLASMS; QUATERNARY AMMONIUM COMPOUNDS; TISSUE DISTRIBUTION;

EID: 78149287643     PISSN: 17435889     EISSN: None     Source Type: Journal    
DOI: 10.2217/nnm.10.84     Document Type: Article

References (34)

1. Immordino ML, Dosio F, Cattel L: Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int. J. Nanomed. 1(3), 297-315 (2006).
2. Lian T, Ho RJ: Trends and developments in liposome drug delivery systems. J. Pharmaceutical Sci. 90(6), 667-680 (2001).
3. Cheong I, Huang X, Bettegowda C et al.: A bacterial protein enhances the release and efficacy of liposomal cancer drugs. Science 314(5803), 1308-1311 (2006).
4. Alexiou C, Arnold W, Klein RJ et al.: Locoregional cancer treatment with magnetic drug targeting. Cancer Res. 60(23), 6641-6648 (2000).
5. Dobson J: Gene therapy progress and prospects: magnetic nanoparticle-based gene delivery. Gene Therapy 13(4), 283-287 (2006).
6. Matsuoka F, Shinkai M, Honda H, Kubo T, Sugita T, Kobayashi T: Hyperthermia using magnetite cationic liposomes for hamster osteosarcoma. Biomagnetic Res. Technol. 25(2), 1-6 (2004).
7. Ross RW, Zietman AL, Xie W et al.: Lymphotropic nanoparticle-enhanced magnetic resonance imaging (LNMRI) identifies occult lymph node metastases in prostate cancer patients prior to salvage radiation therapy. Clinical Imaging 33(4), 301-305 (2009).
8. Gupta AK, Wells S: Surface-modified superparamagnetic nanoparticles for drug delivery: preparation, characterization, and cytotoxicity studies. IEEE Trans. Nanobioscience 3(1), 66-73 (2004).
9. Senyei A, Widder K, Czerlinski G: Magnetic guidance of drug-carrying microspheres. J. Appl. Phys. 49(6), 3578-3583 (1978).
10. Alexiou C, Arnold W, Klein RJ et al.: Locoregional cancer treatment with magnetic drug targeting. Cancer Res 60(23), 6641-6648 (2000).
11. Chan FD, Kirpotin BD, Bunn AP Jr: Synthesis and evaluation of colloidal magnetic iron oxides for the site-specific radiofrequency-induced hyperthermia of cancer. J. Magnetism Magnetic Mater. 122(1-3), 374-378 (1993).
12. Johannsen M, Gneveckow U, Eckelt L et al.: Clinical hyperthermia of prostate cancer using magnetic nanoparticles: presentation of a new interstitial technique. Int. J. Hyperthermia 21(7), 637-647 (2005).
13. Campbell RB, Fukumura D, Brown EB et al.: Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors. Cancer Res. 62(23), 6831-6836 (2002).
14. Dabbas S, Kaushik R, Dandamudi S, Kuesters G, Campbell R: Importance of the liposomal cationic lipid content and type in tumor vascular targeting: physicochemical characterization and in vitro studies using human primary and transformed endothelial cells. Endothelium 15(4), 189-201 (2008).
15. Soenen S, Brisson A, De Cuyper M: Addressing the problem of cationic lipidmediated toxicity: the magnetoliposome model. Biomaterials 30(22), 3691-3701 (2009).
16. Dandamudi S, Campbell RB: The drug loading, cytotoxicity and tumor vascular targeting characteristics of magnetite in magnetic drug targeting. Biomaterials 28(31), 4673-4683 (2007).
17. Saito R, Bringas JR, Mcknight TR et al.: Distribution of liposomes into brain and rat brain tumor models by convection-enhanced delivery monitored with magnetic resonance imaging. Cancer Res. 64(7), 2572-2579 (2004).
18. Rink PA: Magnetic resonance in medicine. Wiley, Oxford, UK (2003).
19. Yoo B, Pagel MD: An overview of responsive MRI contrast agents for molecular imaging. Frontiers Biosci. 13, 1733-1752 (2008).
20. Sun C, Fang C, Stephen Z et al.: Tumortargeted drug delivery and mri contrast enhancement by chlorotoxin-conjugated iron oxide nanoparticles. Nanomedicine 3(4), 495-505 (2008).
21. Medarova Z, Rashkovetsky L, Pantazopoulos P, Moore A: Multiparametric monitoring of tumor response to chemotherapy by noninvasive imaging. Cancer Res. 69(3), 1182-1189 (2009).
22. Fortin-Ripoche J-P, Martina MS, Gazeau F et al.: Magnetic targeting of magnetoliposomes to solid tumors with MR imaging monitoring in mice: feasibility. Radiology 239(2), 415-424 (2006).
23. Dandamudi S, Patil V, Fowle W, Khaw BA, Campbell RB: External magnet enhances antitumor activity and suppresses melanoma metastasis. Cancer Sci. 100(8), 1537-1543 (2009).
24. Owen CS, Sykes NL: Magnetic labeling and cell sorting. J. Immunological Methods 73(1), 41-48 (1984).
25. MR contrast agents for molecular and cellular imaging. In: Molecular Nuclear Medicine the Challenge of Genomics and Proteomics to Clinical Practice. Feinendegen LE, Shreeve WW, Eckelman WC, Bahk Y-W, Wagner HNJ (Eds). Springer Verlag, Berlin, 721-741 (2003).
26. Putz B, Barsky D, Schulten K: Mechanisms of liposomal contrast agents in magnetic resonance imaging. J. Liposome Res. 4(2), 771-808 (1994).
27. Berthier J, Silberzan P: Microfluidics for Biotechnology. Artech House Inc, Norwood, UK, 267-307 (2006).
28. Oberteuffer J: Magnetic separation: a review of principles, devices, and applications. IEEE Trans. Magn. 10(2), 223-238 (1974).
29. Lim JK, Tan DX, Lanni F, Tilton RD, Majetich SA: Optical imaging and magnetophoresis of nanorods. J. Magn. Magn. Mater. 321(10), 1557-1562 (2009).
30. Campbell RB, Ying B, Kuesters GM, Hemphill R: Fighting cancer: from the bench to bedside using second generation cationic liposomal therapeutics. J. Pharmaceutical Sci. 98(2), 411-429 (2009).
31. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K: Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release 65(1-2), 271-284 (2000).
32. Seo WS, Lee JH, Sun X et al.: FeCo/ graphitic-shell nanocrystals as advanced magnetic-resonance-imaging and nearinfrared agents. Nat. Mater. 5(12), 971-976 (2006).
33. Metz S, Lohr S, Settles M et al.: Ferumoxtran-10-enhanced mr imaging of the bone marrow before and after conditioning therapy in patients with non-Hodgkin lymphomas. European Radiol. 16(3), 598-607 (2006).
34. Martina M-S, Fortin J-P, Menager C et al.: Generation of superparamagnetic liposomes revealed as highly efficient MRI contrast agents for in vivo imaging. J. Am. Chem. Soc. 127(30), 10676-10685 (2005).